Business Context and Reporting Period
This Form 8-K reports on the results of the 2023 Annual Meeting of Stockholders held by Aquestive Therapeutics, Inc. on June 21, 2023. The report was filed on June 23, 2023.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Director Election: Gregory B. Brown, M.D., and John S. Cochran were elected as Class II members of the Board of Directors for a three-year term.
- Equity Incentive Plan: The proposal to amend the 2018 Equity Incentive Plan was approved.
- Certificate of Incorporation: The proposal to amend the Amended and Restated Certificate of Incorporation was not approved.
- Independent Auditor: The appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific terms of the failed amendment to the Amended and Restated Certificate of Incorporation to understand the implications for corporate governance.
- Confirm the details of the approved amendment to the 2018 Equity Incentive Plan regarding share reserves or vesting terms.
- Note that KPMG LLP has been ratified as the auditor for the 2023 fiscal year.